• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Hyperfine Inc.

    5/13/25 4:25:28 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HYPR alert in real time by email
    424B5 1 d917572d424b5.htm 424B5 424B5

    Filed Pursuant to Rule 424(b)(5)

    Registration No. 333-275449

    AMENDMENT NO. 2 DATED MAY 13, 2025

    to Prospectus Supplement Dated November 22, 2023

    (To Prospectus Dated November 22, 2023)

    Hyperfine, Inc.

     

    LOGO

    Up to $50,000,000

    Class A Common Stock

     

     

    This Amendment No. 2 to Prospectus Supplement, or this Amendment, amends our prospectus supplement dated November 22, 2023, as amended by Amendment No. 1 dated March 22, 2024, or the Prospectus Supplement. This Amendment should be read in conjunction with the Prospectus Supplement and the accompanying prospectus, or the Prospectus, included in the Registration Statement on Form S-3 filed with the Securities and Exchange Commission on November 9, 2023 (File No. 333-275449), and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus Supplement or the Prospectus. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus Supplement and the Prospectus, and any future amendments or supplements thereto.

    We entered into our sales agreement with B. Riley Securities, Inc., or B. Riley, dated November 9, 2023, or the Sales Agreement, relating to our Class A common stock, par value $0.0001 per share, offered by the Prospectus Supplement and the Prospectus. Pursuant to the Prospectus Supplement and in accordance with the terms of the Sales Agreement, we may offer and sell our Class A common stock having an aggregate offering price of up to $50,000,000 from time to time through or to B. Riley, acting as sales agent or principal. As of May 13, 2025, we have sold 898,119 shares of our Class A common stock pursuant to the Sales Agreement for aggregate gross proceeds of approximately $1.01 million in accordance with the Sales Agreement under the Prospectus Supplement. Consequently, up to approximately $48.99 million remains available for sale under the Sales Agreement pursuant to this Amendment and the Prospectus Supplement.

    Our Class A common stock is listed on The Nasdaq Global Market under the symbol “HYPR.”

    We are filing this Amendment to amend the Prospectus Supplement to increase the amount of our Class A common stock we are eligible to sell pursuant to the Sales Agreement since we are no longer subject to General Instruction I.B.6 of Form S-3. As of March 17, 2025, the date of filing of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, the aggregate market value of our outstanding Class A common stock held by non-affiliates, or the public float, was $95,821,911, which was calculated based on 56,036,205 shares of our outstanding Class A common stock held by non-affiliates as of February 6, 2025, and at a price of $1.71 per share, the closing price of our Class A common stock on February 6, 2025.

    In accordance with the terms of the Sales Agreement, we may offer and sell shares of our Class A common stock having an aggregate offering price of up to $50,000,000 from time to time through or to B. Riley. If our public float decreases in the future such that we become subject to the offering limitations contained in General Instruction I.B.6 of Form S-3, we will file another amendment to the Prospectus Supplement prior to making additional sales.

    Investing in our Class A common stock involves a high degree of risk. See the information contained under “Risk Factors” of the Prospectus Supplement, the Prospectus, and under similar headings in the documents incorporated by reference therein for a discussion of the factors you should carefully consider before deciding to purchase these securities.

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Amendment, the Prospectus Supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

    B. Riley Securities

    The date of this Amendment No. 2 to Prospectus Supplement is May 13, 2025.

    Get the next $HYPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HYPR

    DatePrice TargetRatingAnalyst
    8/11/2022$8.00 → $2.40Overweight → Equal Weight
    Wells Fargo
    5/31/2022$7.00Outperform
    Evercore ISI
    4/14/2022$8.00Overweight
    Wells Fargo
    More analyst ratings

    $HYPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hyperfine Announces Key Executive Appointments to Strengthen its Leadership Position in AI-Powered Portable MRI

      Rafael O'Halloran, PhD, and Rob Fasciano, PhD, bring depth and breadth of experience in imaging and Medtech. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced the appointments of Rob Fasciano, PhD, as Chief Regulatory and Quality Officer, and Rafael O'Halloran, PhD, as Vice President of Technology. These leadership additions were instrumental in the development of the recently FDA-cleared Optive AI™ software and the new, next-generation Swoop® scanner. Their work will greatly aid the rollout of this new technology globally and the d

      6/11/25 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

      This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their patients across multiple sites of care. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced today FDA clearance of its most significant technological advancement to date. The clearance includes an entirely new portable MRI scanner powered by the proprietary Optive AI™ software. This new system delivers the highest level of image quality, functionality, and usability to date, unlocking a new brain im

      6/2/25 8:15:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Announces FDA Clearance of Optive AI™ Software, Introducing the Most Substantial Image Quality Improvement Ever for the Swoop® System

      Latest Swoop® System software delivers a substantial leap in image quality for AI-powered portable MR brain imaging. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced FDA clearance of its next-generation software. This tenth-generation release delivers a substantial leap in image quality for ultra-low-field MR imaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528571999/en/Comparison of Swoop® system FLAIR images showing current image quality and ne

      5/28/25 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hyperfine downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously

      8/11/22 6:32:27 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Evercore ISI initiated coverage on Hyperfine with a new price target

      Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00

      5/31/22 7:16:51 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Wells Fargo initiated coverage on Hyperfine with a new price target

      Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00

      4/14/22 7:32:25 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    SEC Filings

    See more
    • SEC Form 8-K filed by Hyperfine Inc.

      8-K - Hyperfine, Inc. (0001833769) (Filer)

      5/23/25 5:00:17 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Hyperfine, Inc. (0001833769) (Filer)

      5/19/25 4:15:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B5 filed by Hyperfine Inc.

      424B5 - Hyperfine, Inc. (0001833769) (Filer)

      5/13/25 4:25:28 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hyperfine Inc.

      SC 13G - Hyperfine, Inc. (0001833769) (Subject)

      2/13/24 5:06:19 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      2/14/23 4:07:09 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      12/20/22 4:22:37 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Financials

    Live finance-specific insights

    See more
    • Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

      4/29/25 4:28:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

      3/4/25 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

      GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy

      11/12/24 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wolterman Dan

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      6/6/25 4:01:04 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CFO and CAO Hale Brett was granted 300,000 shares (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      5/20/25 5:26:31 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Teisseyre Thomas was granted 300,000 shares, increasing direct ownership by 365% to 382,213 units (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      5/20/25 5:24:42 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

      Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

      12/3/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

      Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

      5/28/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care